ArticleAnnals of translational medicine2022

Combination of Type I and II tyrosine kinase inhibitors-avapritinib and sunitinib-in refractory gastrointestinal stromal tumor after failure to multi-line therapy: a case report.

Xiaodan Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.